A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. — CFSMEATLAS
A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity.
Kedor, Claudia, Freitag, Helma, Meyer-Arndt, Lil et al. · Nature communications · 2022 · DOI
Quick Summary
This study followed 42 people with long-lasting fatigue after COVID-19 infection for six months and compared them to people with similar chronic fatigue from other causes. Most participants experienced moderate to severe fatigue that interfered with daily life. The researchers found that many of these post-COVID patients had reduced hand grip strength and blood markers suggesting possible inflammation and poor blood flow, which may help explain why their bodies struggle to recover.
Why It Matters
This study demonstrates that a substantial proportion of post-COVID patients develop ME/CFS-like illness indistinguishable in severity from classical ME/CFS, helping validate post-COVID-19 fatigue as a legitimate clinical entity. The identification of specific biomarkers associated with symptom severity provides potential biological markers to guide future treatment development and could help distinguish post-COVID ME/CFS from other fatigue conditions.
Observed Findings
Forty-two post-COVID patients demonstrated moderate-to-severe functional impairment six months after infection.
Nineteen (45%) post-COVID patients met Canadian Consensus Criteria for ME/CFS.
Hand grip strength was significantly reduced in most patients compared to healthy controls.
In post-COVID non-ME/CFS patients, grip strength correlated with hemoglobin, interleukin-8, and C-reactive protein.
In post-COVID ME/CFS patients, grip strength correlated with hemoglobin, N-terminal pro-BNP, bilirubin, and ferritin.
Inferred Conclusions
Post-COVID-19 syndrome and ME/CFS show similar clinical severity and functional impairment profiles.
Low-grade inflammation and hypoperfusion may be relevant pathomechanisms in post-COVID ME/CFS development.
Biomarkers associated with grip strength may serve as objective indicators of disease severity in post-COVID fatigue.
Remaining Questions
Do these biomarkers predict progression, recovery, or treatment response over time?
What causes the transition from post-COVID syndrome to ME/CFS in approximately 45% of severely fatigued patients?
What This Study Does Not Prove
This study does not prove that inflammation and hypoperfusion cause ME/CFS symptoms—only that they are associated with symptom severity. The small sample size and observational design limit generalizability and cannot establish whether these biomarkers are causes, consequences, or coincidental findings. Cross-sectional biomarker measurement does not establish temporal relationships or causal mechanisms.